Researchers investigated the use of statins to decrease 28-day mortality among VAP patients. The therapy had initially shown promising results in other studies.
After measuring 28-day, 14-day, intensive care unit and hospital mortality rates between a VAP group receiving statins and a VAP group receiving a placebo, researchers concluded there were no statistically significant differences in survival, and statins were no more effective than a placebo in improving any of the measured mortality rates.
More Articles on Quality:
Blame Game Keeps Healthcare Workers Stuck in Hand Hygiene Compliance Slump
Preventing Needless Hospital Deaths: Q&A With Dr. Ira Williams, Author of “Find the Black Box”
Compounding Pharmacy Meningitis Outbreak Caused 61 Deaths, 749 Infections, Study Says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
